The gold electrode was modified with MXene nanosheets followed by Au@Ag coreshell and Hb complex (Au@Ag CS-Hb/MXene/AuE) for the detection of acrylamide. The prepared MXene was delaminated followed by the etching process and well characterized using X-ray powder diffraction (XRD), Raman spectroscopy, field emission scanning electron microscope (FE-SEM) and transmission electron microscope (TEM). The constructed biosensor showed electrochemical signal for acrylamide in the cyclic voltammetric method. The biosensor was tested in different pH and scan rate variations. The biosensor exhibited a limit of detection of 3.46 μ M with two linear curves in higher and lower concentration ranges. The stability, reproducibility and repeatability studies of Au@Ag CS/Hb/MXene/AuE biosensor showed results emphasizing the good analytical performance of the biosensor. For practical applications, acrylamide was tested in spiked real samples and a good recovery rate was obtained. The proposed biosensor could further be converted to a rapid, portable sensor for acrylamide sensing.
1 February 2019 in Journal of Electroanalytical Chemistry
HPV-16 L1 is an important biomarker of invasive cervical cancerhaving higher carcinogenicity compared to other types of HPV. In this work, a label-free impedimetric immunosensor was developed using gold nanoparticle decorated molybdenum disulfide nanoflower (AuNP/MoS2) modified gold electrode for the detection of HPV-16 L1 antigen. The biorecognition element, anti-HPV-16 antibody (anti-HPV), was adsorbed to the modified electrode surface by spontaneous non-covalent interaction with AuNPs. Two different kinds of AuNPs, namely, citrate capped and cysteamine capped AuNPs were tested for immunosensing activity. The electrochemical data suggested the cit_AuNP/MoS2 platform to be better than cys_AuNP/MoS2 platform, proving its potential use for HPV screening purpose. The selectivity of the biosensor was confirmed with the IgG antigen. The immunosensor has also been proven to be an excellent transducer for the translation to a point-of-care diagnostic device. The developed immunosensor was successfully employed in the quantitative detection of HPV-16 L1 in the linear range of 10 to 1 × 10–13 mg dl−1 with a detection limit of 3.8 × 10–18 mg dl−1. This work reports the lowest LoD for HPV-16 L1. The applicability of the impedimetric immunosensor in human serum was also investigated. It should be noted that the developed biosensor is a feasible and specific tool for the detection and determination of HPV-16 L1.